PDCD1 and thyroid gland carcinoma: Patients with oral squamous cell carcinoma exhibiting a high m6A score are more likely to experience enhanced efficacy from treatments targeting the PD-1 and CTLA-4 pathways (155), lung squamous cell carcinoma (156), soft tissue sarcoma (157), gastric cancer (102), and hepatocellular carcinoma (158), while a low m6A score suggests greater sensitivity to immunotherapy in thyroid cancer (159), NSCLC (160), follicular lymphoma (161), breast cancer (162), and head and neck squamous cell carcinoma (163).